ClinicalThought

Share

Program Content

Activities

  • EGFR TKI Combos
    Current Status of EGFR Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Newly Diagnosed EGFR-Mutated Advanced NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 03, 2021

    Expires: December 02, 2022

  • Uncommon <i>EGFR</i> Mutations
    Management Strategies for Treating Patients With NSCLC and Uncommon EGFR Mutations
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 20, 2022

    Expires: May 19, 2023

  • Combos for EGFR Acquired Resistance
    Rational Combination Strategies in the Treatment of EGFR-Mutated NSCLC With Acquired Resistance to EGFR TKI Therapy: Updates From ASCO 2022
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 13, 2022

    Expires: July 12, 2023

  • Adjuvant Osimertinib
    My Thoughts Regarding Use of Adjuvant Osimertinib for Early-Stage EGFR Mutation–Positive NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2022

    Expires: October 23, 2023

Provided by

ProCE Banner

Supporters

Lilly